Wave Life Sciences (NASDAQ:WVE) Upgraded by StockNews.com to Hold Rating

StockNews.com upgraded shares of Wave Life Sciences (NASDAQ:WVE) from a sell rating to a hold rating in a research report released on Thursday.

A number of other research firms have also weighed in on WVE. Mizuho raised their price objective on Wave Life Sciences from $19.00 to $22.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. Jefferies Financial Group assumed coverage on Wave Life Sciences in a research note on Tuesday, February 25th. They set a “buy” rating and a $26.00 target price on the stock. Truist Financial increased their target price on Wave Life Sciences from $17.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, November 12th. HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of Wave Life Sciences in a research note on Wednesday, November 13th. Finally, B. Riley increased their target price on Wave Life Sciences from $19.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, November 4th. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $22.60.

Wave Life Sciences Stock Up 0.1 %

WVE stock opened at $10.57 on Thursday. Wave Life Sciences has a twelve month low of $4.25 and a twelve month high of $16.74. The firm has a market cap of $1.61 billion, a PE ratio of -9.52 and a beta of -1.09. The business has a 50 day moving average of $11.74 and a 200 day moving average of $11.05.

Hedge Funds Weigh In On Wave Life Sciences

A number of institutional investors and hedge funds have recently modified their holdings of WVE. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Wave Life Sciences by 23.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company’s stock worth $37,000 after buying an additional 856 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Wave Life Sciences by 66.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 23,991 shares of the company’s stock worth $197,000 after buying an additional 9,603 shares during the last quarter. US Bancorp DE boosted its stake in shares of Wave Life Sciences by 53.9% in the 3rd quarter. US Bancorp DE now owns 18,043 shares of the company’s stock worth $148,000 after buying an additional 6,316 shares during the last quarter. Emerald Mutual Fund Advisers Trust boosted its stake in shares of Wave Life Sciences by 16.6% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 2,123,466 shares of the company’s stock worth $17,412,000 after buying an additional 302,528 shares during the last quarter. Finally, Emerald Advisers LLC raised its holdings in Wave Life Sciences by 15.6% in the 3rd quarter. Emerald Advisers LLC now owns 2,881,510 shares of the company’s stock worth $23,628,000 after purchasing an additional 388,280 shares during the period. 89.73% of the stock is currently owned by hedge funds and other institutional investors.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.